Risperidone and Paliperidone: Risk of Intraoperative Floppy Iris Syndrome (IFIS) in Patients Undergoing Cataract Surgery

User Rating: 2 / 5

Star ActiveStar ActiveStar InactiveStar InactiveStar Inactive

Date: 09 June 2014

Description: The NPCB would like to alert healthcare professionals on the risk of intraoperative floppy iris syndrome (IFIS) during and after cataract surgery in patients treated with risperidone or paliperidone-containing products. Patients must be counselled to inform their surgeon about current or prior use of these products before the surgery. In patients with such medication history, the cataract surgery should be approached with caution. If IFIS is suspected, modifications to surgical technique may be required. A Direct Healthcare Professional Communication (DHPC) regarding this issue has been released by Janssen, a division of Johnson & Johnson (M) Sdn. Bhd., and the package inserts of all related products will be updated accordingly.

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400



Image   Image   Image   Image  


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Thursday 20 June 2024, 10:17:13.
© Copyright 2023 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA


Main Menu English